share_log

NAYA Biosciences Announces Development Of NY-500 Novel AI-Optimized PD-1 X VEGF Bifunctional Antibody

NAYA Biosciences Announces Development Of NY-500 Novel AI-Optimized PD-1 X VEGF Bifunctional Antibody

NAYA生物科学公司宣布开发NY-500新型人工智能优化的PD-1与VEGF双功能抗体
Benzinga ·  01/06 21:32

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications

PD-1 x VEGF抗体显示出有潜力超越免疫检查点抑制剂成为多种肿瘤适应症的标准治疗。

• NAYA aiming to initiate clinical trials in early 2026

• NAYA计划于2026年初启动临床试验

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发